Compare HTZ & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HTZ | NRIX |
|---|---|---|
| Founded | 1918 | 2009 |
| Country | United States | United States |
| Employees | 26000 | N/A |
| Industry | Rental/Leasing Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.6B |
| IPO Year | N/A | 2020 |
| Metric | HTZ | NRIX |
|---|---|---|
| Price | $7.01 | $16.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $4.93 | ★ $30.50 |
| AVG Volume (30 Days) | ★ 10.3M | 1.3M |
| Earning Date | 05-07-2026 | 04-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $76,987,000.00 |
| Revenue This Year | $5.00 | N/A |
| Revenue Next Year | $3.61 | $40.12 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $3.78 | $8.20 |
| 52 Week High | $9.39 | $22.50 |
| Indicator | HTZ | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 72.67 | 58.77 |
| Support Level | $4.94 | $16.02 |
| Resistance Level | $7.35 | $16.71 |
| Average True Range (ATR) | 0.54 | 0.92 |
| MACD | 0.20 | 0.18 |
| Stochastic Oscillator | 92.60 | 82.73 |
Hertz Global Holdings Inc is engaged principally in the business of renting vehicles through its Hertz, Dollar and Thrifty brands. The company has two reportable segments: i) Americas RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in the U.S., Canada, Latin America and the Caribbean, ii) International RAC: Rental of vehicles, as well as sales of vehicles and value-added services, in locations other than the U.S., Canada, Latin America and the Caribbean. The company maintains a substantial network of company-operated rental locations, a majority of which are in Europe, and has franchisees and partners that operate rental locations under brands. Geographical markets include North America, Europe, Pacific Asia, Middle East and Africa, and Latin America.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.